Health Care Distributors

Virax Biolabs

Virax Biolabs Group Ltd Completes First UK Clinical Trial Recruitment and Advances Scientific Dossier

Virax Biolabs released FY2026 Semi-Annual earnings on December 2, 2025 (EST) with actual revenue of USD 1.608 K and EPS of USD -0.491

Virax Biolabs released FY2026 Q2 earnings on December 2, 2025 (EST), actual revenue USD 804 (forecast USD 10 K), actual EPS USD -0.2455 (forecast USD -0.34)

Virax Biolabs released FY2026 Q1 earnings on December 2, 2025 (EST), actual revenue USD 804 (forecast USD 10K), actual EPS USD -0.2455 (forecast USD -0.34)

Virax Biolabs Group Ltd. Completes UK Clinical Study and Plans US Research in 2026

Virax Biolabs Group Limited Collaborates with Emory University for ViraxImmune™ Clinical Research

Virax Biolabs Releases Investor Presentation on Next-Generation Immune Diagnostic Products

Virax Biolabs released FY2025 Q4 earnings on July 2, 2025 (EST), actual revenue USD 689 (forecast USD 10 K), actual EPS USD -0.3792 (forecast USD -0.33)

Virax Biolabs released FY2025 9 Months Earnings on July 2, 2025 (EST), with actual revenue of USD 5.642 K and EPS of USD -1.2692

Virax Biolabs released FY2025 Q3 earnings on July 2, 2025 (EST) with actual revenue of USD 689 and EPS of USD -0.3792

Virax Biolabs Reports Significant Revenue Decline for Fiscal Year 2025

Virax Biolabs released FY2025 annual earnings on July 2 (EST), actual revenue USD 6.331 K (forecast USD 25 K), actual EPS USD -1.6248 (forecast USD -1.48)

Virax Biolabs CFO Jason Davis Resigns

Virax Biolabs Presents T-Cell Research and Platform Expansion

HC Wainwright Initiates Coverage on Virax Biolabs with Buy Rating and Target Price of $3

Virax Biolabs Begins Patient Recruitment in the UK to Evaluate T Cell Dysfunction in Post-Acute Infection Syndromes

Virax Biolabs Supports HHS's Focus on Vaccine Efficacy Transparency

Virax Biolabs released FY2025 Q2 earnings on November 20 (EST), actual revenue USD 2.476 K, actual EPS USD -0.4449

Virax Biolabs released FY2025 H1 earnings on November 20, 2024 (EST), actual revenue 4953 USD, actual EPS -0.8899

Virax Biolabs released FY2025 Q1 earnings on November 20, 2024 (EST) with actual revenue of 2.477 K USD and EPS of -0.445

A SPAC III Acquisition

PicoCELA

Davis Commodities

Society Pass

ECD Automotive Design

Gauzy

Bristol-Myers Squibb Company

A SPAC III ACQUISITION CORP. COM NPV CL A (SUBS/RTS)02/01/2026

Paranovus ENT Tech

Cue BioPharma

Cencora

Henry Schein

McKesson

Cardinal Health

AdaptHealth

Akso Health

Owens & Minor

Pomdoctor

Wellgistics Health

Cosmos Health

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap